NASP Speciality Pharmacy Podcast

Breaking Down the 2026 Consolidated Appropriations Act and Its Impact on Specialty Pharmacy | NASP Specialty Pharmacy Podcast

51 min · 11. Juni 2026
Episode Breaking Down the 2026 Consolidated Appropriations Act and Its Impact on Specialty Pharmacy | NASP Specialty Pharmacy Podcast Cover

Beschreibung

In this episode, Sheila Arquette, President & CEO of NASP, speaks with Jonathan L. Swichar, Duane Morris Pharmacy Litigation Group Chair, and Bradley A. Wasser, Duane Morris Pharmacy Litigation Group Partner. They discuss the 2026 Consolidated Appropriations Act and its landmark PBM reform provisions that impact pharmacy network access and transparency. These expert litigators go into detail about what specialty pharmacies should expect as federal agencies enforce the new law and what opportunities and challenges lie ahead for specialty pharmacies.

Kommentare

0

Sei die erste Person, die kommentiert

Melde dich jetzt an und werde Teil der NASP Speciality Pharmacy Podcast-Community!

Loslegen

2 Monate für 1 €

Dann 4,99 € / Monat · Jederzeit kündbar.

  • Podcasts nur bei Podimo
  • 20 Stunden Hörbücher / Monat
  • Alle kostenlosen Podcasts

Alle Folgen

61 Folgen

Episode From Innovation and Integration to Impact: Advancing Health System Specialty Pharmacy at UC Davis Health | NASP Specialty Pharmacy Podcast Cover

From Innovation and Integration to Impact: Advancing Health System Specialty Pharmacy at UC Davis Health | NASP Specialty Pharmacy Podcast

In this episode, Sheila Arquette, President & CEO of NASP, speaks with David G. Mitchell, PharmD, MBA, CSP, FCPhA, Assistant Chief Pharmacy Officer of Specialty Pharmacy & Home Delivery and Ruth Chen, PharmD, MHA, Manager of the Specialty Pharmacy Hub at UC Davis Health in Sacramento. They look at how UC Davis Health has built and scaled one of California’s most integrated health-system specialty pharmacy programs. Dr. Mitchell shares how being embedded within clinics, care teams, and the EHR enables specialty pharmacy to deliver differentiated clinical and operational value while navigating payer, policy, and access challenges in a rapidly evolving landscape. Dr. Chen discusses why a focused rare disease strategy is essential for health-system specialty pharmacies. She walks through the challenges that existed prior to implementing a centralized rare disease hub model and how those challenges shaped the development of a coordinated, pharmacy-led approach that supports patients and providers across complex therapies. Together, this conversation highlights how structure, strategy, and leadership enable innovation, workforce growth, and improved patient care.

10. Feb. 202645 min